ArticleArXiv2026
Proton therapy range uncertainty reduction using vendor-agnostic tissue characterization on a virtual photon-counting CT head scan.
Article in ArXiv, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this work, we proposed virtual imaging simulators as an alternative approach to experimental validation of beam range uncertainty in complex patient geometry using a computational model of a human head and a photon-counting CT scanner. We validate the accuracy of stopping power ratio (SPR) calculations using a conventional stoichiometric calibration approach and a prototype software, TissueXplorer. A validated CT simulator (DukeSim) was used to generate photon-counting CT projections of a computational head model, which were reconstructed with an open-source toolbox (ASTRA). The dose of 2 Gy was delivered through protons in a single fraction to target two different cases of nasal and brain tumors with a single lateral beam angle. Ground truth treatment plan was made directly on the computational head model using clinical treatment planning software (RayStation). This plan was then recalculated on the corresponding CT images for which SPR values were estimated using both the conventional method and the prototype software TissueXplorer. The mean percentage difference in estimating the stopping power ratio with TissueXplorer in all head tissues inside the scanned volume was 0.28%. Stopping power ratios obtained with this method showed smaller dose distribution differences from the ground truth plan than the conventional stoichiometric calibration method on the computational head model. Virtual imaging offers an alternative approach to validation of the SPR prediction from CT imaging, as well as its effect on the dose distribution and thus downstream clinical outcomes. According to this simulation study, software solutions that utilize spectral information, such as TissueXplorer, hold promise for more accurate prediction of the stopping power ratio than the conventional stoichiometric approach.
Identifiers
41479447PMC12755245What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.